Chronic Pain, Osteoarthritis
Conditions
Keywords
Osteoarthritis, Pain, Assessment, Tapentadol, Centrally acting analgesic, Chronic pain due to osteoarthritis
Brief summary
The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release in participants suffering from severe chronic pain due to osteoarthritis of the knee who are taking either WHO Step I or Step II analgesics or no regular analgesics. This is a clinical effectiveness trial designed to establish a link between anticipated clinical outcomes and the clinical practice by means of selected measures of clinical and subject-reported outcome. The trial will compare the effectiveness of previous analgesic treatment (either WHO Step I or Step II analgesics or no regular analgesics) with that of tapentadol hydrochloride prolonged release (PR) treatment during defined periods of evaluation.
Interventions
DRUGTapentadol
Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day. Maintenance Period: Participants continuing on the dose established in the previous period.
Sponsors
Grünenthal GmbH
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Participants have signed an Informed Consent Form indicating that they understand the purpose of and the procedures required for the trial and are willing to participate in it. 2. Participants are men or non-pregnant, non-lactating women. Sexually active women must be postmenopausal, surgically sterile, or practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double barrier method, contraceptive patch, male partner sterilization) before entry and throughout the trial. Women of childbearing potential must have a negative pregnancy test at screening. 3. Participants must be appropriately communicative to verbalize and to differentiate with regard to location and intensity of the pain. 4. Participants must be at least 40 years of age. 5. Participants must have a diagnosis of osteoarthritis of the knee based on the American College of Rheumatology (ACR) classification criteria: * Knee pain and * Radiographic osteophytes or * Knee pain and * Aged 40 years or above, and * Morning stiffness of less than 30 minutes of duration and * Crepitus on motion. 6. Participants must have pain at the reference joint which has been present for at least 3 months. 7. Participant's pain must require a strong analgesic (defined as WHO Step III) as judged by the Investigator. 8. Participants must report a rate of satisfaction with their previous analgesic regimen not exceeding fair on a participant satisfaction with treatment scale (5-point VRS). 9. If under regular, daily pretreatment: * Participants must be taking a WHO Step I or Step II analgesic medication for osteoarthritis of the knee on a daily basis for at least 2 weeks prior to the Screening Visit. * The Investigator considers dose increase of WHO Step I analgesics (as mono- or combination therapy) and/or continuation with or dose increase of WHO Step II analgesics inadequate for the individual participant, whatever applicable. * Participants must have an average pain intensity score (NRS 3) greater than 5 points during the last 3 days prior to the Screening Visit. OR if no regular analgesic pretreatment is reported: * Participants must have an average pain intensity score (NRS-3)greater than 6 points in the last 3 days prior to the Screening Visit and related to osteoarthritis.
Exclusion criteria
1. Presence of a clinically significant disease or laboratory findings that in the Investigator's opinion may affect efficacy or safety assessments. 2. Presence of active systemic or local infection, that may, in the opinion of the Investigator, affect the efficacy, quality of life/function or safety assessments. 3. History of alcohol or drug abuse, or suspicion thereof in the Investigator's judgment. 4. Presence of concomitant autoimmune inflammatory conditions. 5. Known history of or laboratory values reflecting severe renal impairment. 6. Known history of moderately or severely impaired hepatic function. 7. History of or active hepatitis B or C within the past 3 months or history of HIV infection. 8. History of seizure disorder or epilepsy. 9. Any of the following within 1 year: mild/moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm. Severe traumatic brain injury within 15 years (consisting of 1 or more of the following: brain contusion, intracranial hematoma, either unconsciousness or post-traumatic amnesia lasting more than 24 h) or residual sequelae suggesting transient changes in consciousness. 10. Pregnant or breast-feeding. 11. History of allergy to, or hypersensitivity to tapentadol hydrochloride or its excipients, or contraindications related to tapentadol hydrochloride including: * Participants with acute or severe bronchial asthma or hypercapnia. * Participants who have or are suspected of having paralytic ileus. 12. Employees of the Investigator or trial site, with direct involvement in this trial or other trials under the direction of the Investigator or trial site, as well as family members of employees of the Investigator. 13. Participation in another trial concurrently or within 4 weeks prior to the Screening Visit. 14. Known to or suspected of not being able to comply with the protocol and the use of the investigational medicinal product. 15. Use of monoamine oxidase inhibitors within 14 days before the Screening Visit. 16. Non-stable dosing of selective serotonin reuptake inhibitors within 30 days before the Screening Visit (Doses must remain stable during the trial). 17. Osteoarthritis in a flare state. 18. Use of intra-articular injections of hyaluronic acid in the reference joint within 3 months before the Screening Visit. 19. Presence of conditions other than osteoarthritis of the reference joint that could confound the assessment or self-evaluation of pain, e.g., anatomical deformities, significant skin conditions such as abscess or syndromes with widespread pain such as fibromyalgia. Participants with osteoarthritis at joints other than the reference joint will not be excluded as long as the reference joint is the source of main pain and disability. 20. History and clinical signs at the reference joint of crystal-induced (e.g., gout, pseudo-gout), metabolic, infectious and autoimmune disease. 21. Any concomitant painful condition that could interfere with the participants' trial assessments or with their ability to differentiate the current joint pain from other painful conditions. 22. Any painful procedures during the trial (e.g., major surgery, including the reference joint) that may, in the opinion of the Investigator, affect the efficacy or safety assessments. 23. Pending litigation due to chronic pain or disability. 24. Intake of Step III analgesics within the 30 days prior to the Screening Visit.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Primary Endpoint is Defined as the Change From Week -1 of the Average Pain Intensity Score on an 11-point NRS-3 at Week 6. | Baseline to end of week 6 | For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale(NRS) where a score of 0 indicated no pain and a score of 10 indicated pain as bad as you can imagine. The value indicates the change from the baseline value on the 0 to 10 scale. A Negative value indicates a reduction in pain intensity from the baseline average pain intensity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Average Pain Intensity After 6 Weeks of Tapentadol PR Treatment | Baseline; End of Week 6 (6 Weeks) | For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale(NRS) where a score of 0 indicated no pain and a score of 10 indicated pain as bad as you can imagine. The value indicates the change from the baseline value on the 0 to 10 scale. A Negative value indicates a reduction in pain intensity from the baseline average pain intensity. |
| Change in Average Pain Intensity After 12 Weeks of Tapentadol PR Treatment | Baseline; End of Week 12 (12 Weeks) | For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale(NRS) where a score of 0 indicated no pain and a score of 10 indicated pain as bad as you can imagine. The value indicates the change from the baseline value on the 0 to 10 scale. A Negative value indicates a reduction in pain intensity from the baseline average pain intensity. |
| EuroQol-5 (EQ-5D) Health Status Index Outcome Over Time | Baseline; End of Week 6 (6 Weeks) | The participant scored the EuroQol-5. This is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating full health and 0 representing dead. The positive values indicate that during the study the health status improved. |
| Change in Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS) | Baseline; End of Week 6 (6 Weeks) | EuroQoL-5D Health State Visual Analog Scale (VAS) is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The values indicated represent the change from the baseline, a positive value indicates an improvement. |
| Patient Global Impression of Change | Baseline; End of Week 6 (6 Weeks) | In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period. The participant is requested to choose one of seven categories. Scores range from very much improved to very much worse. |
| Average Pain Intensity Before the Start of Tapentadol Treatment | Baseline | For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale (NRS)where a score of 0 indicated no pain and a score of 10 indicated pain as bad as you can imagine. |
| Participant's Satisfaction With Previous Analgesic Treatment | Baseline | Participants were requested to rate their previous analgesic medication on a 5-point scale. Previous medication was rated as excellent, very good, good, fair and poor. |
| Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol. | Baseline; End of Week 6 (6 Weeks) | Participants were requested to rate their tapentadol (new) analgesic medication on a 5-point scale. The medication was rated as excellent, very good, good, fair and poor. |
| Baseline Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee | Baseline | Western Ontario McMaster Questionnaire (WOMAC) Global Score: WOMAC is measured with a Likert ordinal scale (the participant gives one of 5 possible answers) A higher score indicate that a symptom is bothersome or disabling. The WOMAC is a self-administered questionnaire and has 24 questions: Pain, Stiffness and Physical Function. The possible scores range from 0-20 for pain, 0-8 for stiffness, 0-68 for physical function and these are then summed 0-96 for the global score. A lower score indicates a lower level of symptoms and or disability. |
| Change From Baseline in the Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week at Week 6 | Baseline; End of Week 6 (6 Weeks) | The WOMAC is a self-administered questionnaire and has 24 questions: Pain, Stiffness and Physical Function. The possible scores range from 0-20 for pain, 0-8 for stiffness, 0-68 for physical function and these are then summed 0-96 for the global score. The negative value indicates that there has been an improvement since baseline, the higher the value the greater the change since baseline. |
| Change From Baseline in the Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week at Week 12 | Baseline; End of Week 12 (12 Weeks) | The WOMAC is a self-administered questionnaire and has 24 questions: Pain, Stiffness and Physical Function. The possible scores range from 0-20 for pain, 0-8 for stiffness, 0-68 for physical function and these are then summed 0-96 for the global score. The negative value indicates that there has been an improvement since baseline, the higher the value the greater the change since baseline. |
| Clinical Global Impression of Change | Baseline; End of Week 6 (6 Weeks) | In the Clinical Global Impression of Change (CGIC) the clinician indicates the perceived change over the treatment period. The clinician is requested to choose one of seven categories. Scores range from very much improved to very much worse. |
Countries
France, Germany, Poland, Spain, United Kingdom
Participant flow
Recruitment details
The enrollment of the first participant was on the 21 September 2009 and was completed on 02 September 2010 (when the last subject completed the last follow-up examination).
Pre-assignment details
The Trial had a duration of 13 weeks. The one week Observation Period did not involve dosing with Tapentadol. For Tapentadol analyses purposes the first 6 weeks of dosing with Tapentadol are reported as one period, Titration and Optimal Dose Period. The last 6 weeks on Tapentadol are reported as the Maintenance Period.
Participants by arm
| Arm | Count |
|---|---|
| Tapentadol PR All participants started with 50 mg tapentadol hydrochloride PR (twice daily). The dose of tapentadol hydrochloride PR was adjusted to a level that provided adequate analgesia (upwards or downwards on a weekly basis as needed). After 5 weeks the dose of tapentadol hydrochloride PR was kept stable. Participants were permitted a maximum dose of 250 mg twice a day (500 mg total daily dose). Tapentadol hydrochloride IR 50 mg (no more than twice daily; at least 4 hours apart) was considered as medication for acute pain episodes however, participants were not permitted to dose tapentadol hydrochloride IR once 500 mg tapentadol hydrochloride PR dose was reached. | 200 |
| Total | 200 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Maintenance Period | Adverse Event | 5 |
| Maintenance Period | Lack of Efficacy | 2 |
| Maintenance Period | Other Reason | 7 |
| Maintenance Period | Withdrawal by Subject | 2 |
| Titration and Optimal Dose Period | Adverse Event | 19 |
| Titration and Optimal Dose Period | Lack of Efficacy | 5 |
| Titration and Optimal Dose Period | Non-Compliance | 1 |
| Titration and Optimal Dose Period | Other reason | 4 |
| Titration and Optimal Dose Period | Withdrawal by Subject | 11 |
Baseline characteristics
| Characteristic | Tapentadol PR |
|---|---|
| Age, Customized 40 years and older | 67.4 years STANDARD_DEVIATION 10.8 |
| Baseline Average Pain Intensity | 7.5 Units on a scale STANDARD_DEVIATION 1.08 |
| Region of Enrollment France | 24 participants |
| Region of Enrollment Germany | 91 participants |
| Region of Enrollment Poland | 6 participants |
| Region of Enrollment Spain | 57 participants |
| Region of Enrollment United Kingdom | 22 participants |
| Sex: Female, Male Female | 135 Participants |
| Sex: Female, Male Male | 65 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 142 / 200 |
| serious Total, serious adverse events | 8 / 200 |
Outcome results
Primary
The Primary Endpoint is Defined as the Change From Week -1 of the Average Pain Intensity Score on an 11-point NRS-3 at Week 6.
For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale(NRS) where a score of 0 indicated no pain and a score of 10 indicated pain as bad as you can imagine. The value indicates the change from the baseline value on the 0 to 10 scale. A Negative value indicates a reduction in pain intensity from the baseline average pain intensity.
Time frame: Baseline to end of week 6
Population: All participants who had at least one dose of study medication and one post-baseline pain intensity assessment. Last Observation Carried Forward (LOCF).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tapentadol PR | The Primary Endpoint is Defined as the Change From Week -1 of the Average Pain Intensity Score on an 11-point NRS-3 at Week 6. | -3.4 Units on a scale | Standard Deviation 2.1 |
Secondary
Average Pain Intensity Before the Start of Tapentadol Treatment
For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale (NRS)where a score of 0 indicated no pain and a score of 10 indicated pain as bad as you can imagine.
Time frame: Baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tapentadol PR | Average Pain Intensity Before the Start of Tapentadol Treatment | 7.5 units on a scale | Standard Deviation 1.08 |
Secondary
Baseline Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee
Western Ontario McMaster Questionnaire (WOMAC) Global Score: WOMAC is measured with a Likert ordinal scale (the participant gives one of 5 possible answers) A higher score indicate that a symptom is bothersome or disabling. The WOMAC is a self-administered questionnaire and has 24 questions: Pain, Stiffness and Physical Function. The possible scores range from 0-20 for pain, 0-8 for stiffness, 0-68 for physical function and these are then summed 0-96 for the global score. A lower score indicates a lower level of symptoms and or disability.
Time frame: Baseline
Population: Number of participants with data available
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tapentadol PR | Baseline Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee | 53.6 units on a scale | Standard Deviation 14.58 |
Secondary
Change From Baseline in the Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week at Week 12
The WOMAC is a self-administered questionnaire and has 24 questions: Pain, Stiffness and Physical Function. The possible scores range from 0-20 for pain, 0-8 for stiffness, 0-68 for physical function and these are then summed 0-96 for the global score. The negative value indicates that there has been an improvement since baseline, the higher the value the greater the change since baseline.
Time frame: Baseline; End of Week 12 (12 Weeks)
Population: Number of participants with data available
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tapentadol PR | Change From Baseline in the Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week at Week 12 | -27.6 units on a scale | Standard Deviation 19.52 |
Secondary
Change From Baseline in the Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week at Week 6
The WOMAC is a self-administered questionnaire and has 24 questions: Pain, Stiffness and Physical Function. The possible scores range from 0-20 for pain, 0-8 for stiffness, 0-68 for physical function and these are then summed 0-96 for the global score. The negative value indicates that there has been an improvement since baseline, the higher the value the greater the change since baseline.
Time frame: Baseline; End of Week 6 (6 Weeks)
Population: Number of participants with data available
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tapentadol PR | Change From Baseline in the Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week at Week 6 | -21.0 units on a scale | Standard Deviation 18.82 |
Secondary
Change in Average Pain Intensity After 12 Weeks of Tapentadol PR Treatment
For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale(NRS) where a score of 0 indicated no pain and a score of 10 indicated pain as bad as you can imagine. The value indicates the change from the baseline value on the 0 to 10 scale. A Negative value indicates a reduction in pain intensity from the baseline average pain intensity.
Time frame: Baseline; End of Week 12 (12 Weeks)
Population: Number of participants with data available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tapentadol PR | Change in Average Pain Intensity After 12 Weeks of Tapentadol PR Treatment | -4.4 units on a scale | Standard Deviation 1.91 |
Secondary
Change in Average Pain Intensity After 6 Weeks of Tapentadol PR Treatment
For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale(NRS) where a score of 0 indicated no pain and a score of 10 indicated pain as bad as you can imagine. The value indicates the change from the baseline value on the 0 to 10 scale. A Negative value indicates a reduction in pain intensity from the baseline average pain intensity.
Time frame: Baseline; End of Week 6 (6 Weeks)
Population: Number of participants with data available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tapentadol PR | Change in Average Pain Intensity After 6 Weeks of Tapentadol PR Treatment | -3.8 units on a scale | Standard Deviation 1.94 |
Secondary
Change in Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS)
EuroQoL-5D Health State Visual Analog Scale (VAS) is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The values indicated represent the change from the baseline, a positive value indicates an improvement.
Time frame: Baseline, End of Week 12 (12 Weeks)
Population: Number of participants with data available
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tapentadol PR | Change in Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS) | 19.5 Units on a scale | Standard Deviation 26.6 |
Secondary
Change in Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS)
EuroQoL-5D Health State Visual Analog Scale (VAS) is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The values indicated represent the change from the baseline, a positive value indicates an improvement.
Time frame: Baseline; End of Week 6 (6 Weeks)
Population: Number of participants with data available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tapentadol PR | Change in Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS) | 15.8 Units on a scale | Standard Deviation 22.8 |
Secondary
Clinical Global Impression of Change
In the Clinical Global Impression of Change (CGIC) the clinician indicates the perceived change over the treatment period. The clinician is requested to choose one of seven categories. Scores range from very much improved to very much worse.
Time frame: Baseline; End of Week 12 (12 Weeks)
Population: Number of participants with data available
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tapentadol PR | Clinical Global Impression of Change | Very Much Improved | 28 Participants |
| Tapentadol PR | Clinical Global Impression of Change | Much Improved | 68 Participants |
| Tapentadol PR | Clinical Global Impression of Change | Minimally Improved | 27 Participants |
| Tapentadol PR | Clinical Global Impression of Change | No Change | 2 Participants |
| Tapentadol PR | Clinical Global Impression of Change | Minimally Worse | 0 Participants |
| Tapentadol PR | Clinical Global Impression of Change | Much Worse | 0 Participants |
| Tapentadol PR | Clinical Global Impression of Change | Very Much Worse | 0 Participants |
Secondary
Clinical Global Impression of Change
In the Clinical Global Impression of Change (CGIC) the clinician indicates the perceived change over the treatment period. The clinician is requested to choose one of seven categories. Scores range from very much improved to very much worse.
Time frame: Baseline; End of Week 6 (6 Weeks)
Population: Number of participants with data available
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tapentadol PR | Clinical Global Impression of Change | Very Much Improved | 14 Participants |
| Tapentadol PR | Clinical Global Impression of Change | Much Improved | 88 Participants |
| Tapentadol PR | Clinical Global Impression of Change | Minimally Improved | 47 Participants |
| Tapentadol PR | Clinical Global Impression of Change | No Change | 7 Participants |
| Tapentadol PR | Clinical Global Impression of Change | Minimally Worse | 2 Participants |
| Tapentadol PR | Clinical Global Impression of Change | Much Worse | 1 Participants |
| Tapentadol PR | Clinical Global Impression of Change | Very Much Worse | 1 Participants |
Secondary
EuroQol-5 (EQ-5D) Health Status Index Outcome Over Time
The participant scored the EuroQol-5. This is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating full health and 0 representing dead. The positive values indicate that during the study the health status improved.
Time frame: Baseline; End of Week 12 (12 Weeks)
Population: Number of participants with data available
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tapentadol PR | EuroQol-5 (EQ-5D) Health Status Index Outcome Over Time | 0.27 Units on a scale | Standard Deviation 0.34 |
Secondary
EuroQol-5 (EQ-5D) Health Status Index Outcome Over Time
The participant scored the EuroQol-5. This is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating full health and 0 representing dead. The positive values indicate that during the study the health status improved.
Time frame: Baseline; End of Week 6 (6 Weeks)
Population: Number of participants with data available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tapentadol PR | EuroQol-5 (EQ-5D) Health Status Index Outcome Over Time | 0.23 Units on a scale | Standard Deviation 0.3 |
Secondary
Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol.
Participants were requested to rate their tapentadol (new) analgesic medication on a 5-point scale. The medication was rated as excellent, very good, good, fair and poor.
Time frame: Baseline; End of Week 6 (6 Weeks)
Population: Number of participants with data available
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tapentadol PR | Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol. | Excellent | 16 participants |
| Tapentadol PR | Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol. | Very Good | 39 participants |
| Tapentadol PR | Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol. | Good | 88 participants |
| Tapentadol PR | Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol. | Fair | 17 participants |
| Tapentadol PR | Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol. | Poor | 0 participants |
Secondary
Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol.
Participants were requested to rate their tapentadol (new) analgesic medication on a 5-point scale. The medication was rated as excellent, very good, good, fair and poor.
Time frame: Baseline; End of Week 12 (12 Weeks)
Population: Number of participants with data available
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tapentadol PR | Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol. | Poor | 1 participants |
| Tapentadol PR | Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol. | Excellent | 16 participants |
| Tapentadol PR | Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol. | Very Good | 45 participants |
| Tapentadol PR | Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol. | Good | 54 participants |
| Tapentadol PR | Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol. | Fair | 9 participants |
Secondary
Participant's Satisfaction With Previous Analgesic Treatment
Participants were requested to rate their previous analgesic medication on a 5-point scale. Previous medication was rated as excellent, very good, good, fair and poor.
Time frame: Baseline
Population: Number of participants with data available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tapentadol PR | Participant's Satisfaction With Previous Analgesic Treatment | Excellent | 0 participants |
| Tapentadol PR | Participant's Satisfaction With Previous Analgesic Treatment | Very Good | 0 participants |
| Tapentadol PR | Participant's Satisfaction With Previous Analgesic Treatment | Good | 4 participants |
| Tapentadol PR | Participant's Satisfaction With Previous Analgesic Treatment | Fair | 132 participants |
| Tapentadol PR | Participant's Satisfaction With Previous Analgesic Treatment | Poor | 62 participants |
Secondary
Patient Global Impression of Change
In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period. The participant is requested to choose one of seven categories. Scores range from very much improved to very much worse.
Time frame: Baseline; End of Week 12 (12 Weeks)
Population: Number of participants with data available
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tapentadol PR | Patient Global Impression of Change | Very Much Improved | 23 Participants |
| Tapentadol PR | Patient Global Impression of Change | Much Improved | 64 Participants |
| Tapentadol PR | Patient Global Impression of Change | Minimally Improved | 33 Participants |
| Tapentadol PR | Patient Global Impression of Change | No Change | 5 Participants |
| Tapentadol PR | Patient Global Impression of Change | Minimally Worse | 0 Participants |
| Tapentadol PR | Patient Global Impression of Change | Much Worse | 0 Participants |
| Tapentadol PR | Patient Global Impression of Change | Very Much Worse | 0 Participants |
Secondary
Patient Global Impression of Change
In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period. The participant is requested to choose one of seven categories. Scores range from very much improved to very much worse.
Time frame: Baseline; End of Week 6 (6 Weeks)
Population: Number of participants with data available
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tapentadol PR | Patient Global Impression of Change | Very Much Improved | 14 Participants |
| Tapentadol PR | Patient Global Impression of Change | Much Improved | 75 Participants |
| Tapentadol PR | Patient Global Impression of Change | Minimally Improved | 58 Participants |
| Tapentadol PR | Patient Global Impression of Change | No Change | 8 Participants |
| Tapentadol PR | Patient Global Impression of Change | Minimally Worse | 2 Participants |
| Tapentadol PR | Patient Global Impression of Change | Much Worse | 2 Participants |
| Tapentadol PR | Patient Global Impression of Change | Very Much Worse | 0 Participants |